Glutamine Synthetase Antibody - #DF7341

Figure 3 Glutamine-restrictive therapy benefits from the low levels of ATF4. A) Tissue microarray of NSCLC patients with tissue immunofluorescence assay. Representative tissue immunofluorescence images with ATF4 (Red), GS (Green), and GLS (Pink). White arrows indicate GLS filaments. Scale bar: 10 µm. B) Correlation analysis between the number of relative GLS filament structures and positive cell density of ATF4 in the tissue microarray. C) Correlation analysis between positive cell density of GS and ATF4 in the tissue microarray. D) Schematic of tumors after intratumoral injection of shATF4 lentivirus with glutamine-deficient diet and 2% glutamine diet in the established xenograft model (n = 6 per group). E) Tumor images (n = 6 per group). F) Tumor volume, body weight, and tumor weight of nude mice with intratumoral injection of shATF4 lentivirus and different glutamine diets (n = 6 per group). G) Protein expression levels in xenograft tumors after intratumoral injection of shATF4 lentivirus and different glutamine diets (n = 3 independent experiments). H) Relative glutamine content in different glutamine diet groups (n = 6 independent experiments). Glutamine concentrations of 2% and 0% glutamine diet are represented by 2%Q and -Q, respectively. Data are shown as mean ± SD. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. Data were analyzed using two-tailed Student's t-tests (F, G, H) in GraphPad Prism 9.5.0. Source unprocessed blots are provided.